

($p=0.04$). Finally, higher CMV-IgG correlated with diffused cutaneous SSc form ($p=0.023$) and nephropathy ($p=0.036$).

Conclusions: The seroprevalence of EBV and CMV positivity was found significantly higher in the sample of SSc patients. EBV seropositivity (VCA-IgG) was present nearly in the totality of patients (98%). Of relevance, the high presence of CMV-IgG (93%) and CMV-IgM (44.9%) in SSc patients: the last correlated linearly with higher pulmonary arterial pressure values. EBV and CMV infections, among the supposed triggers in several autoimmune diseases, might also play a role in SSc patients, at least with progressive disease.

REFERENCES:

[1] Rickinson AB, et al. Fields virology. Philadelphia: Lippincott Williams and Wilkins; 2001. pp. 2575–2627
 [2] Kano Y1, et al. Dermatol Sci. 2000;22:196–204
 [3] Armon Y, et al. Ann N Y Acad Sci. 2009 Sep;1173:627–32.
 [4] van den Hoogen F, et al. Ann Rheum Dis. 2013;72:1747–1755.

Disclosure of Interest: None declared

DOI: 10.1136/annrheumdis-2018-eular.6755


AB0724 **CARDIO-PULMONARY DISEASE MANAGEMENT IN PATIENTS WITH SYSTEMIC SCLEROSIS: CARDIO-RHEUMATOLOGY CLINIC AND PATIENT CARE STANDARDISATION PROPOSAL**

A. Spinella¹, F. Lumetti¹, A.V. Mattioli², F. Coppi³, R. Rosario³, E. Cocchiara¹, M. Colaci⁴, C. Ferni¹, C. Salvarani¹, D. Giuggioli⁵. ¹Scleroderma Unit, Chair of Rheumatology; ²Department of Surgical, Medical and Dental Department of Morphological Sciences related to Transplant, Oncology and Regenerative Medicine; ³Chair of Cardiology, University of Modena and RE, Modena; ⁴Internal Medicine Unit, University of Catania, Catania; ⁵Scleroderma Unit, Chair of Rheumatology, University of Modena and RE, Modena, Italy

Background: Systemic sclerosis (SSc) is a chronic connective tissue disease characterised by endothelial dysfunction, dysregulation of fibroblasts with excessive fibrosis of the skin and internal organs and autoimmune abnormalities. Cardio-pulmonary manifestations are common in SSc and their detection in the early stage of the disease as well as their careful follow-up are mandatory in order to counteract their impact on the overall disease outcome. Despite the need of establishing a proper methodology, literature provides few reports about this issue.

Objectives: To evaluate the activity of our Cardio-Rheumatology Clinic in order to optimise diagnostic management of cardio-pulmonary disease in SSc patients.

Methods: We retrospectively analysed data from 350 consecutive SSc patients referred to our University-based Rheumatology Centre and SSc Unit (F/M 308/42; lc/dcSSc 45/305; mean age 50.8±14.7 years; mean disease duration 10.9±7.0 years). All patients underwent general and cardio-pulmonary assessment, in particular they were evaluated in the Cardio-Rheumatology Clinic. The following parameters were considered: physical examination; past and current drugs; blood tests, in particular Erythrocyte sedimentation rate-ESR, C-reactive protein-CRP, CPK enzymes, troponin, NT-pro-BNP, d-dimer, serum autoantibodies, 25-OH-vitamin D; capillaroscopy; pulmonary function tests; high resolution scan of the lungs (HRCT); standard electrocardiogram (ECG) and 24 hour Holter ECG monitoring; Doppler echocardiography; cardiac stress test; coronary angiography and right heart catheterization (RHC); cardiac MRI and CT; vascular ultrasound (intima-media-thickness, carotid-femoral and brachial-ankle pulse-wave-velocity). The clinicians decided to perform these examinations according to clinical picture and current methodologies.



Abstract AB0724 – Figure 1

Results: In the last 12 months we assessed 300 patients with 1st-level screening (cardio-rheumatologic evaluation, standard ECG, Doppler echocardiography, pulmonary function tests, thoracic imaging). Among 2nd-level, 30 procedures of 24 hour Holter ECG and 15 RHC tests were performed. Cardiac MRI, coronary CT angiography and vascular ultrasound were assessed, when requested, as 3rd-level examinations (30 procedures). After 1 year we observed a mean time of 10±5 days between request and clinical cardio-rheumatologic evaluation, 20±12 days to perform 1st-level screening, 25±15 days to execute the 2nd-level examinations. Figure-1 shows Cardio-Rheumatology algorithm for the management of SSc cardio-pulmonary disease.

Conclusions: The activity of our Cardio-Rheumatology Clinic optimises the cardio-pulmonary SSc assessment, determining an early detection of these harmful complications with reduced waiting times which are critical issues. Screening algorithms are useful to stratify the risk and to establish the most appropriate diagnostic-therapeutic protocols, improving outcome of scleroderma patients. The development of a cardio-pulmonary risk score and the standardisation of a patient care approach, according to international quality indexes, could represent further tools to optimise SSc management.

Disclosure of Interest: None declared

DOI: 10.1136/annrheumdis-2018-eular.7420

AB0725 **SEVERE DYSPHAGIA “POOR PROGNOSTIC MARKER” IN IDIOPATHIC INFLAMMATORY MYOPATHIES**

A.C. Costi, L. Garcia, C. Pena, A. Testi, P. Sansinanea, R. Aguila, M. Pera, S. Velloso, F. Savy, M. Garcia. *Reumatology, HIGA San Martín, La Plata, Argentina*

Background: In Idiopathic Inflammatory Myopathies (MII), 18%–20% of patients have dysphagia.

Objectives: To evaluate the frequency of dysphagia in patients with MII, association with other manifestations of the disease, treatment and evolution.

To evaluate clinical characteristics and evolution of severe dysphagia.

To compare clinical characteristics and evolution of mild-moderate versus severe dysphagia.

Methods: Retrospective, observational study. Patients with a diagnosis of MII were included according to modified classification criteria of Bohan and Peter. Demographic, clinical and complementary studies were recorded. Serious dysphagia was considered: contraindication of oral feeding. Descriptive statistics were performed. Chi2 test, Student’s test or Mann Whitney as appropriate.

Results: We included 91 of 106 patients evaluated from 1992 to 2017: 76% female, mean age at diagnosis 48±14 years. 53% presented dysphagia: mild/moderate 62.5% (30/48 pts), severe 37.5% (18/48). Idiopathic dermatomyositis was the most frequent MII in these patients (71%). In patients with dysphagia, proximal muscle weakness was 90%, weakness of neck muscles 45%, weakness of respiratory muscles 27%.

A significant association was found between dysphagia and weakness of respiratory muscles, weak neck muscles, glucocorticoid pulses, gammaglobulin, grave infections and death. (Data not shown in the summary).

In patients with **severe dysphagia**, we observed a significant association with the requirement for mechanical ventilation, hospitalisation in an intensive care unit, serious infections and death (table 1).

When comparing mild-moderate dysphagia vs severe dysphagia, a statistically significant association was found with neck muscles weakness, respiratory muscle weakness, glucocorticoid pulses, gamma globulin use, requirement for mechanical ventilation, hospitalisation in an intensive care unit, severe infections and mortality (table 2).

Abstract AB0725 – Table 1

	Severe dysphagia (SI) 18/91	Severe dysphagia (NO) 72/91	p	OR	IC 95%
Weakness of respiratory muscles	8/18	6/63	0 00 054	7,6	2,1–26,6
Weak neck muscles	8/16	6/63	0 00 129	8	2,5–26
Glucocorticoid pulses	12/18	8/69	<0,0001	15	4,4–51,9
Gammaglobulin	10/18	7/72	<0,0008	11,60	0,8–10
Intensive therapy unit	7/18	8/72	0,0046	5	1,5–16,8
Mechanical respiratory assistance	6/18	5/72	0002	6,70	1,7–25
Grave Infections	10/17	11/66	0,0003	7	2,2–22,8
Death	12/18	9/72	<0,0001	14	4,2–46,6